Massive RSV vaccine study uses real-world data to see if shots prevent severe illness

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion: Vaccinated Cohort Patients must meet all the following inclusion criteria to be eligible for inclusion in the vaccinated cohort: Adults meet the age criteria at the index date. Non-pregnant at the index date. Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date. Have a documented administration of ABRYSVO® (or AREXVY®，mRESVIA® in the later phase) in Epic Cosmos on or after August 2023. The index date for vaccinated individuals will be defined as the date of RSV vaccination. Unvaccinated Cohort Patients must meet all the following inclusion criteria to be eligible for inclusion in the unvaccinated cohort: Adults meet the age criteria at the index date. Non-pregnant at the index date. Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date. Have no documented receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date. The index date for unvaccinated individuals will be defined as the start date of each sequential trial (e.g., 1st date of each month) in which they met eligibility criteria. Exclusion: Vaccinated Cohort Patients meeting any of the following criteria will not be included in the vaccinated cohort: Individual with receipt of any RSV vaccine in Epic Cosmos prior to the trial start date, as defined above (applicable to all analyses except for the analysis of recipients of multiple doses). Non-US residents. Unvaccinated Cohort Patients meeting any of the following criteria will not be included in the unvaccinated cohort: Individual with receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date, as defined above. Non-US residents. Patients must meet all the inclusion criteria and none of the exclusion criteria to meet eligibility requirements.